Protagonist Therapeutics (PTGX) News Today $51.52 +1.31 (+2.61%) As of 01:58 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PTGX Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent July 2025 June 2025 May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 Time Period Illinois Municipal Retirement Fund Reduces Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)July 2 at 4:17 AM | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Trading Down 7.2% - What's Next?July 1 at 4:10 PM | marketbeat.comProtagonist Announces Nomination of PN-477, an Oral and Injectable GLP-1R, GIPR, and GCGR Triple Agonist Peptide Development Candidate for ObesityJune 30 at 4:40 PM | usatoday.comCan Protagonist Take On Eli Lilly's Next-Generation Obesity Treatment?June 30 at 4:40 PM | msn.comPTGX Protagonist Therapeutics, Inc. - Seeking AlphaJune 26, 2025 | seekingalpha.comProtagonist Therapeutics, Takeda Pharmaceutical Announce Positive Phase 3 Rusfertide Results for Polycythemia VeraJune 24, 2025 | msn.comProtagonist Therapeutics’ SWOT analysis: biotech stock poised for growthJune 20, 2025 | investing.comCiti Rates Protagonist Therapeutics (PTGX) as Buy Protagonists Drugs OpportunityJune 20, 2025 | msn.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stock Position Lifted by Exchange Traded Concepts LLCJune 19, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Now Covered by CitigroupJune 17, 2025 | marketbeat.comAssenagon Asset Management S.A. Sells 7,367 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 17, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from BrokeragesJune 14, 2025 | marketbeat.comGAMMA Investing LLC Raises Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 13, 2025 | marketbeat.comArturo Md Molina Sells 10,000 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX) StockJune 12, 2025 | insidertrades.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Insider Arturo Md Molina Sells 10,000 SharesJune 11, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Upgraded to "Hold" at Wall Street ZenJune 8, 2025 | marketbeat.comHennion & Walsh Asset Management Inc. Sells 6,008 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 7, 2025 | marketbeat.comShort Interest in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Decreases By 13.6%June 5, 2025 | marketbeat.com9 Analysts Assess Protagonist Therapeutics: What You Need To KnowJune 4, 2025 | benzinga.comProtagonist Therapeutics' (PTGX) "Buy" Rating Reaffirmed at HC WainwrightJune 3, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Stake Lifted by Mackenzie Financial CorpJune 2, 2025 | marketbeat.comProtagonist and Takeda Announce ASCO Plenary Presentation Highlighting Full 32-Week Results from Phase 3 VERIFY Study of Rusfertide, Showing Reductions in Phlebotomy, Improved Hematocrit Control in Polycythemia VeraJune 1, 2025 | businesswire.comWellington Management Group LLP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 1, 2025 | marketbeat.comUBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC Has $11.11 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 1, 2025 | marketbeat.comNuveen Asset Management LLC Sells 80,877 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)June 1, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Downgraded to Sell Rating by Wall Street ZenJune 1, 2025 | marketbeat.com340,974 Shares in Protagonist Therapeutics, Inc. (NASDAQ:PTGX) Acquired by Toronto Dominion BankMay 30, 2025 | marketbeat.comD. E. Shaw & Co. Inc. Sells 21,121 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 29, 2025 | marketbeat.comBank of America Corp DE Has $5.21 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 29, 2025 | marketbeat.comProtagonist Therapeutics’ SWOT analysis: stock poised for growth amid clinical advancementsMay 28, 2025 | investing.comProtagonist Therapeutics (PTGX) Rose on Positive Trial OutcomeMay 27, 2025 | msn.comCache Advisors LLC Makes New $392,000 Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 26, 2025 | marketbeat.comWoodline Partners LP Boosts Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 23, 2025 | marketbeat.comToronto Dominion Bank Makes New $13.16 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 23, 2025 | marketbeat.comMan Group plc Has $6.10 Million Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 23, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Receives Average Rating of "Buy" from AnalystsMay 22, 2025 | marketbeat.comProtagonist Therapeutics (NASDAQ:PTGX) Receives "Buy" Rating from HC WainwrightMay 21, 2025 | marketbeat.comSoleus Capital Management L.P. Makes New $10.62 Million Investment in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 21, 2025 | marketbeat.comDeutsche Bank AG Boosts Stake in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 21, 2025 | marketbeat.comRTW Investments LP Has $212.24 Million Stock Position in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 18, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Bought by Northern Trust CorpMay 15, 2025 | marketbeat.comJefferies Financial Group Inc. Has $57.50 Million Holdings in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 13, 2025 | marketbeat.comCrestline Management LP Invests $489,000 in Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 13, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Sold by Algert Global LLCMay 13, 2025 | marketbeat.comHC Wainwright Brokers Reduce Earnings Estimates for PTGXMay 13, 2025 | marketbeat.comDriehaus Capital Management LLC Sells 105,654 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 12, 2025 | marketbeat.comWedbush Issues Optimistic Outlook for PTGX EarningsMay 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Purchased by Farallon Capital Management LLCMay 11, 2025 | marketbeat.comProtagonist Therapeutics, Inc. (NASDAQ:PTGX) Shares Acquired by AQR Capital Management LLCMay 11, 2025 | marketbeat.comThe Manufacturers Life Insurance Company Purchases 8,576 Shares of Protagonist Therapeutics, Inc. (NASDAQ:PTGX)May 11, 2025 | marketbeat.com Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address PTGX Media Mentions By Week PTGX Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. PTGX News Sentiment▼0.430.90▲Average Medical News Sentiment PTGX News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. PTGX Articles This Week▼66▲PTGX Articles Average Week Get Protagonist Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for PTGX and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Dr. Reddy's Laboratories News Ascendis Pharma A/S News Viatris News Qiagen News Moderna News Blueprint Medicines News Verona Pharma PLC American Depositary Share News BridgeBio Pharma News Roivant Sciences News Revolution Medicines News Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:PTGX) was last updated on 7/2/2025 by MarketBeat.com Staff From Our PartnersUtah’s New Oil FindThe Real Reason 218,000 Acres Just Vanished The government just quietly leased 218,000 acres in the middle ...Stansberry Research | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | Sponsored379 passengers walked away from thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredGold is soaring. Here’s how to get paid from itGold just broke through $3,300… And while the headlines shout about price targets, something even more powe...Investors Alley | SponsoredAI Meltdown Imminent: Dump These Stocks Now!If you have any money in the markets, especially in AI stocks… Please click here to see Elon Musk’s new inv...Paradigm Press | SponsoredIsrael-Iran WAR Could Destroy Trump's PresidencyThe missiles are already flying. Israel and Iran are now in direct military conflict — and this couldn't ha...American Alternative | SponsoredIs Elon's empire crumbling?The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered ...Brownstone Research | SponsoredThe $7 company helping Nvidia build the world’s first trillion-dollar robot …Michael Robinson has been at the forefront of the technology market for over 40 years. Spotting some profit...Weiss Ratings | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Protagonist Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Protagonist Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free PTGX Stock Alerts